Neurocrine Biosciences News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

06.02.18	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results (PR Newswire)
05.02.18	Hyundai's Super Bowl LII Commercial: "Hope Detector" (PR Newswire)
08.01.18	CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY (RTTNews)
07.01.18	Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer (PR Newswire)
07.01.18	Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones (PR Newswire)
05.01.18	LiveXLive Acquires Slacker Radio (PR Newswire)
07.12.17	Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference (PR Newswire)
04.12.17	Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms (PR Newswire)
29.11.17	Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting (PR Newswire)
21.11.17	Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference (PR Newswire)
20.11.17	Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer (PR Newswire)
14.11.17	Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry (PR Newswire)
09.11.17	INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association (PR Newswire)
08.11.17	Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare Conference (PR Newswire)
07.11.17	Neurocrine to Present Data on the Patient Impact of Tardive Dyskinesia from the RE-KINECT Study at the 2017 Neuroscience Education Institute Congress (PR Newswire)
03.11.17	DRNA Soars On NASH Deal, JUNO Transcends Expectations, FMI On Solid Footing (RTTNews)
02.11.17	NBIX Delivers, MNTA's Biosimilar Drug Trial Fails, No FDA Panel Meet For RARE (RTTNews)
01.11.17	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q3 Earnings Report (RTTNews)
01.11.17	Neurocrine Biosciences Reports Third Quarter 2017 Results (PR Newswire)
01.11.17	AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain (PR Newswire)
31.10.17	Neurocrine Biosciences to Present at the Credit Suisse 26th Annual Healthcare Conference (PR Newswire)
30.10.17	FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch (RTTNews)
27.10.17	AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain (PR Newswire)
25.10.17	Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA® in Children and Adolescents with Tourette Syndrome (PR Newswire)
24.10.17	Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2017 Results (PR Newswire)
24.10.17	FDA Approves New Use For Soliris, HSTM In Good Health, BYSI Springs A Surprise (RTTNews)
05.10.17	Neurocrine Announces FDA Approval Of 80 Mg Capsule Of INGREZZA - Quick Facts (RTTNews)
05.10.17	Neurocrine Announces FDA Approval of 80 mg INGREZZA® (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD) (PR Newswire)
18.09.17	Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences (PR Newswire)
15.09.17	Neurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congress (PR Newswire)
14.09.17	Beyond20 Senior Advisor Selected to Speak on Building a Unified Service Catalog at the 2017 Cherwell Global Conference (PR Newswire)
06.09.17	AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain (PR Newswire)
31.08.17	Taco Bell's Naked Egg Taco Revealed On Menus Nationwide (PR Newswire)
30.08.17	Neurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conference (PR Newswire)
14.08.17	Breakfast Technical Briefing on Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma (PR Newswire)
03.08.17	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q2 Earnings Report (RTTNews)
03.08.17	Neurocrine Biosciences Reports Second Quarter 2017 Results (PR Newswire)
28.07.17	Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results (PR Newswire)
21.07.17	Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer (PR Newswire)
10.07.17	Technical Snapshots for These Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma (PR Newswire)
09.06.17	Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference (PR Newswire)
02.06.17	Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders (PR Newswire)
01.06.17	Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference (PR Newswire)
30.05.17	Technical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Neurocrine Biosciences (PR Newswire)
25.05.17	Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX... (RTTNews)
24.05.17	MRK's Keytruda Scores Another FDA Nod, NBIX Disappoints, SBPH Achieves It (RTTNews)
23.05.17	Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome (PR Newswire)
18.05.17	Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting (PR Newswire)
17.05.17	AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis (PR Newswire)
11.05.17	Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

mehr

30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell
28.08.24		Schwacher Handel: NASDAQ Composite zum Handelsstart schwächer